Galasko, Douglas R, Peskind, Elaine, Clark, Christopher M., Quinn, Joseph F., Ringman, John M., Jicha, Gregory A., Cotman, Carl, Cottrell, Barbara, Montine, Thomas J., Thomas, Ronald G., Aisen, Paul

Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.; Design: Double-blind, placebo-controlled clinical trial.; Setting: Academic medical centers.; Participants: Subjects with mild to moderate Alzheimer disease.; Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C […]

Siemers, Eric R., Friedrich, Stuart, Dean, Robert A., Gonzales, Celedon R., Farlow, Martin R., Paul, Steven M., Demattos, Ronald B.

Objectives: Active and passive immunization strategies have been suggested as possible options for the treatment of Alzheimer disease (AD). LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.; Methods: Patients with mild to moderate AD were screened and selected for inclusion. Initial screening was performed for 54 subjects, […]

Troussière, Anne-Cécile, Monaca Charley, Christelle, Salleron, Julia, Richard, Florence, Delbeuck, Xavier, Derambure, Philippe, Pasquier, Florence, Bombois, Stéphanie

Background: It is essential to detect and then treat factors that aggravate Alzheimer’s disease (AD). Here, we sought to determine whether or not continuous positive airway pressure (CPAP) therapy for sleep apnoea syndrome (SAS) slows the rate of cognitive decline in mild-to-moderate AD patients.; Methods: Between January 2003 and June 2011, we included consecutive, mild-to-moderate […]